Similar articles

• Global transmission of oseltamivir-resistant influenza.

  Moscona A. Moscona A. N Engl J Med. 2009 Mar 5;360(10):953-6. doi: 10.1056/NEJMp0900648. Epub 2009 Mar 2. N Engl J Med. 2009. PMID: 19258250 No abstract available.
• Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.

  Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, Yamauchi S, Kawamura K, Matsuura S, Nishimura M, Iwaki N, Kashiwagi S. Kawai N, et al. Clin Infect Dis. 2009 Dec 15;49(12):1828-35. doi: 10.1086/648424. Clin Infect Dis. 2009. PMID: 19911968
• Drug resistance. A 'wimpy' flu strain mysteriously turns scary.

  Enserink M. Enserink M. Science. 2009 Feb 27;323(5918):1162-3. doi: 10.1126/science.323.5918.1162. Science. 2009. PMID: 19251605 No abstract available.
• [Significance of the neuraminidase inhibitor oseltamivir for the management of seasonal influenza].

  Ruf BR, Sandow P, Lehmann P, Del Piero L, Skopnik H. Ruf BR, et al. Dtsch Med Wochenschr. 2008 Jun;133(23):1259-64. doi: 10.1055/s-2008-1077250. Dtsch Med Wochenschr. 2008. PMID: 18509804 Review. German. No abstract available.
• The use of antiviral agents for the management of severe influenza.

  Smith JR, Ariano RE, Toovey S. Smith JR, et al. Crit Care Med. 2010 Apr;38(4 Suppl):e43-51. doi: 10.1097/CCM.0b013e3181c85229. Crit Care Med. 2010. PMID: 19935416 Review.